| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
STORY UPDATE
GAITHERSBURG, Md.—August 15, 2006—Emergent BioSolutions announced it has registered with the U.S. Securities and Exchange Commission for a potential $86-million IPO. The number and price of shares have not yet been determined. J.P. Morgan Securities Inc. will serve as sole book-running manager for the offering.
 
 
GAITHERSBURG, Md.—Emergent BioSolutions, a privately-held biopharma­ceutical company, in June signed an agree­ment with sanofi pasteur, the vaccines busi­ness of the sanofi-aventis Group, giving the company exclusive, worldwide rights to Emergent BioSolutions' proprietary pro­teins and related technology to develop a novel vaccine against Neisseria meningitidis serogroup B bacterial infections.
 
While there are effective purified polysac­charide and conjugate vaccines available to protect against the other major meningococ­cal serogroups, currently there is no vaccine to protect against Neisseria meningitidis serogroup B infections. Even with intensive medical treatment, meningococcal infection has a fatality rate of up to 10 percent, and approximately 15 percent of survivors are left with serious disability, such as loss of limbs, deafness or brain damage.
 
"Our agreement with sanofi pasteur is an important step forward in the development of a critically needed vaccine to prevent one of the world's deadliest childhood diseases," says Fuad El-Hibri, chairman and CEO of Emergent. "This agree­ment is also consistent with our strategy of selectively establishing relationships with leading phar­maceutical and biotechnology companies for the commercializa­tion of certain of our product can­didates."
 
It is also an opportunity that might not have presented itself had Emergent not acquired U.K.-based vaccine company Microscience just over a year ago.
 
"Microscience had already initi­ated discussions with sanofi before the acquisition," recalls Kyle Keese, senior VP, marketing and commu­nications for Emergent. "So that acquisition, in addition to bring­ing us a significant commercial pipeline of preclinical and clinical-stage vaccines, also brought in the collaboration with sanofi."
 
The two companies will joint­ly evaluate and develop a pool of four antigen candidates that could serve as the basis of a multivalent subunit vaccine against Neisseria meningitidis infection. Emergent BioSolutions identified these pro­tein candidates using its patented Signature-Tagged Mutagenesis functional genomics technol­ogy—another inheritance from the Microscience acquisition—in combination with functional pro­teomics techniques.
 
Under the terms of the agree­ment, Emergent will have primary responsibility for product devel­opment activities from the current preclinical testing through Phase I clinical trials, Keese reports. Then sanofi pasteur will have pri­mary responsibility for product development activities from ini­tiation of Phase 2 studies through to regulatory approval, and for all commercialization activities including world- wide sales and marketing.
 
Children aged 6 months to 2 years are at the highest risk of sero­group B meningococcal infection, with teenagers also at increased risk compared to adults—and death can come quickly, within 24 hours of the onset of symptoms. As such, both Emergent and sano­fi see this work as filling a major unmet public health need.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A doctor wearing blue gloves and a white lab coat with a stethoscope around their neck holds a rendering of a digestive system on a glass pane with a swirled blue background.

Connecting the gut and liver to enhance drug development

Explore how a dual-organ microphysiological system connects human gut and liver tissue to bridge gaps in predicting how drugs behave in the body.
A syringe draws liquid from a glass vial, with several glass ampoules reflected on a glossy surface in the background

Turning up the heat: thermal analysis for biotherapeutics

Explore essential thermal stability techniques to ensure the safety, quality, and efficacy of biologic drugs.
A 3D-rendered image of a pink and white twisted RNA strand floating against a green, blurred cellular background.

Cutting the time and cost out of plasmid generation

Discover a hassle-free path to obtaining long, complex plasmid DNA.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue